MedWatch

Analyst: Lundbeck’s patent expirations can cost close to a billion

There is pressure on both the top and bottom line in Lundbeck, says an analyst, and the pressure is growing. The company can expect patent expirations on two drugs to cut almost a billion dollars of the company’s turnover in coming years.

Foto: Lundbeck / PR

Drug sales in Danish company Lundbeck are still dropping and there is no change on the horizon in the immediate future, says analyst Peter Aabo, Nordic Bioinvestor.com. The general increase in turnover in Q1 was simply facilitated by a rapid growth in licensing revenue from a collaboration agreement with Japanese partner Otsuka and divestiture of a small portfolio of drugs in the US.

“The pressure will grow even more in the short and medium term, as the company can expect a decrease in turnover of 5 billion kroner (USD 870 million) in the coming two years due to patent expirations on existing drugs,” Peter Aabo writes in an analysis in Økonomisk Ugebrev.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier